Details

Autor(en) / Beteiligte

• Hsieh, Ming‐Shun
• Hung, Pin‐Shun
• Hsieh, Vivian Chia‐Rong
• Liao, Shu‐Hui
• How, Chorng‐Kuang

Titel

Association between thiazolidinedione use and rheumatoid arthritis risk in patients with type II diabetes, a population‐based, case‐control study

Ist Teil von

• International journal of clinical practice (Esher), 2021-03, Vol.75 (3), p.e13804-n/a

Ort / Verlag

England: Hindawi Limited

Erscheinungsjahr

2021

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Aim A previous study revealed that PPARγ agonists have anti‐inflammatory effects in rheumatoid arthritis (RA). Furthermore, some studies have shown that type 2 diabetes mellitus (T2DM) may elicit the development of RA. In this study, we aimed to investigate whether the use of thiazolidinediones (TZDs) is associated with a lower risk of developing RA in patients with T2DM. Methods Based on the Taiwan National Health Insurance Research Database, we conducted a nationwide case‐control study. The selected cases were patients with T2DM who were diagnosed with RA between 2000 and 2013. The controls were retrieved at a ratio of 1:4 by propensity score matching. Logistic regression was conducted to evaluate whether TZD use lowers the risk of RA in patients with T2DM. The dose‐response effect was examined according to the total TZD dose, within 2 years before the index date (the first diagnosis date of RA), and TZD doses were divided into four groups by cumulative Defined Daily Dose (cDDD): <30, 31‐90, 91‐365, and >365 cDDDs. Results A total of 3605 cases and 14 420 controls were included in this study. After adjusting for age, sex, baseline comorbidities, the results demonstrated that TZD use did not significantly reduce the risk of RA in patients with T2DM (adjusted OR = 0.91, 95% CI 0.81‐1.02). In the subgroup analysis by total TZD exposure dose within 2 years, 91‐365 cDDDs of TZD had a lower risk of RA development, aOR = 0.87 (95% CI 0.71‐1.06) and >365 cDDDs of TZD, aOR = 0.85 (95% CI 0.73‐1.01). In the trend test, P was <.05. Conclusions TZD use might reduce the risk of RA in patients with T2DM, but it was non‐statistically significant. Further research is necessary to assess this association.